Author： Guinea Jesúús Bouza Emilio
Publisher： Future Medicine
ISSN： 1746-0913
Source： Future Microbiology, Vol.3, Iss.6, 2008-12, pp. : 603-615
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Invasive fungal infections (IFIs) are an important cause of morbidity and mortality. Isavuconazole (BAL4815) is a promising novel broad-spectrum triazole in late-stage clinical development that has proven to be active in vitro against Aspergillus, Candida and Cryptococcus neoformans, the most common agents of IFIs. Furthermore, isavuconazole has a pharmacokinetic profile that allows oral and intravenous administration with no severe toxicity. In vivo data from animal models are also encouraging. However, very little information on clinical efficacy is available. Four clinical trials are currently in progress to demonstrate the safety and efficacy of isavuconazole for the treatment and prevention of IFIs. In the absence of clinical and cost data, the real possibilities of this agent as a competitor for the treatment and prevention of IFIs in the clinical setting are still unknown.
Related content
Access to resources
Recommend
Tailored treatment of invasive fungal infections
Future Microbiology, Vol. 3, Iss. 2, 2008-04 ,pp. :
Meeting the challenge of invasive fungal infections: part 1
Future Microbiology, Vol. 8, Iss. 9, 2013-09 ,pp. :